Form 4 for AMGN Amgen
Accepted 2025-02-21 00:00:00 ET · period of report 2025-02-19 · accession 0001127602-25-006282 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-21 | 2025-02-19 | AMGN | REESE DAVID M | EVP, CTO | M - OptEx | $156.35 | +8,711 | 70.9K | +14% | +$1.36M |
| DM | 2025-02-21 | 2025-02-19+ | AMGN | REESE DAVID M | EVP, CTO | S - Sale+OE | $301.56 | -33.9K | 36.9K | -48% | -$10.23M |
| D | 2025-02-21 | 2025-02-19 | AMGN | REESE DAVID M | EVP, CTO | M - OptEx | $0.00 | -8,711 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-19 | M | A | 8,711 | $156.35 | 70,858 | D | — | — | (F1) These shares were acquired in connection with the exercise of stock options expiring on May 3, 2026. |
| 2 | Common | Common Stock | 2025-02-19 | S | D | 8,711 | $293.22 | 62,147 | D | — | — | (F2) The price reported is an average price. The prices ranged from $291.90 to $295.97 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer. |
| 3 | Common | Common Stock | 2025-02-21 | S | D | 25,225 | $304.44 | 36,922 | D | — | — | (F3) The price reported is an average price. The prices ranged from $297.19 to $305.33 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer. (F4) These shares include 707 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
| 4 | Derivative | Nqso (Right to Buy) | 2025-02-19 | M | D | 8,711 | $0.00 | 0 | D | $156.35 · 2018-05-03 to 2026-05-03 | 8,711 Common Stock |